Lantern: Latest data on DNA damage therapy for pancreatic cancer
- A Persistent Crisis: The Looming Specter of Drug Shortages in United States
- Rabies: The fatality rate nearly 100% once symptoms appear
- Human Brain Continues to Grow: Study Shows Increase in Size and Complexity
- CRISPR Genome Editing: From Molecular Principles to Therapeutic Applications
- Metformin Helps Immune System Better Recognize Cancer Cells
- Highlights of Prostate Cancer Research at the 2024 EAU Congress
Lantern announced the latest data on DNA damage therapy for pancreatic cancer: The treatment reduced tumors in mice by more than 90%, and tumors in a quarter of mice completely resolved
Lantern: Latest data on DNA damage therapy for pancreatic cancer. Lantern Pharma announced the latest preclinical data of the pancreatic cancer treatment drug LP-184 developed in cooperation with the Pancreatic Cancer Institute of Fox Chase Cancer Center.
Experimental results showed that in pancreatic tumor xenograft mouse models, LP-184 significantly and rapidly reduced pancreatic tumors by more than 90% within 8 weeks, while untreated mice increased tumor volume in 8 weeks. Times more.
Lantern Pharma announced the latest preclinical data of the pancreatic cancer treatment drug LP-184 developed in cooperation with the Pancreatic Cancer Institute of Fox Chase Cancer Center.
Experimental results showed that in pancreatic tumor xenograft mouse models, LP-184 significantly and rapidly reduced pancreatic tumors by more than 90% within 8 weeks, while untreated mice increased tumor volume in 8 weeks. Times more.
Among them, after 8 weeks of treatment, 1 of the 4 mice treated with LP-184 had tumor disappeared, and the average remaining tumor size of 3 mice was about 7% of the original tumor, and it was smaller than the untreated tumor 146 times.
LP-184 is a DNA alkylating agent that exerts a therapeutic effect by destroying the DNA in cancer cells, which usually overexpress certain biomarkers.
Lantern believes that LP-184 can selectively destroy DNA in tumors that express high levels of PTGR1 enzyme, and that PTGR1 enzyme is highly expressed in a variety of solid tumors.
In this study, CRISPR knockout data confirmed that PTGR1 plays a leading role in LP-184 in coordinating tumor responsiveness to LP-184. The study used CRISPR editing to silence the PTGR1 gene in pancreatic cancer cells, and the results showed that pancreatic cancer cells had almost no response to LP-184, and those pancreatic cancer cells with PTGR1 expression (not affected by gene editing) had an enhanced response to LP-184 , Pancreatic cancer cells die.
And the analysis of the Lantern data platform shows that 35%-40% of pancreatic cancer transcriptomes in clinical databases have up-regulated expression of PTGR1.
Therefore, the use of specific genetic characteristics to select patients can increase the likelihood of success in clinical trials, and can focus future clinical trials on those patients who are likely to benefit the most from treatment, and ultimately may improve the survival of cancer patients. Rate.
Lantern plans to initiate an IND application in the second half of this year to promote phase I clinical trials. In addition to pancreatic cancer, LP-184 is also undergoing preclinical development for indications such as prostate cancer, ovarian cancer, and glioblastoma.
(source:internet, reference only)
Disclaimer of medicaltrend.org
Important Note: The information provided is for informational purposes only and should not be considered as medical advice.
